Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7)

Mark N. Gaze; Daria Handkiewicz-Junak; Raquel Hladun; Theodore W. Laetsch; Caryn Sorge; Richard Sparks; Simon Wan; Antony Ceraulo; Aneta Kluczewska-Galka; Cristina Gámez-Cenzano; Lisa J. States; Riham El Khouli; Paola Aimone; Kevin Perraud; Gabor Kollar; Fariba Khanshan; Lars Blumenstein; Fazia Brouri; Anne Laure Giraudet

doi:10.1007/s00259-025-07344-6

Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7)

Mark N. Gaze
, Daria Handkiewicz-Junak
, Raquel Hladun
, Theodore W. Laetsch
, Caryn Sorge
, Richard Sparks
, Simon Wan
, Antony Ceraulo
, Aneta Kluczewska-Galka
, Cristina Gámez-Cenzano
, Lisa J. States
, Riham El Khouli
, Paola Aimone
, Kevin Perraud
, Gabor Kollar
, Fariba Khanshan
, Lars Blumenstein
, Fazia Brouri
, Anne Laure Giraudet

Research output: Contribution to journal › Comment/debate

Abstract

The article Safety and dosimetry of [¹⁷⁷Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study, written by Mark N. Gaze, Daria Handkiewicz-Junak, Raquel Hladun, Theodore W. Laetsch, Caryn Sorge, Richard Sparks, Simon Wan, Antony Ceraulo, Aneta Kluczewska-Galka, Cristina Gámez-Cenzano, Lisa J. States, Riham El Khouli, Paola Aimone, Kevin Perraud, Gabor Kollar, Fariba Khanshan, Lars Blumenstein, Fazia Brouri, and Anne-Laure Giraudet, was originally published under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.

Original language	English
Pages (from-to)	5211-5212
Number of pages	2
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	52
Issue number	13
DOIs	https://doi.org/10.1007/s00259-025-07344-6
State	Published - Nov 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-025-07344-6

Fingerprint

Dive into the research topics of 'Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7)'. Together they form a unique fingerprint.

Cite this

Gaze, M. N., Handkiewicz-Junak, D., Hladun, R., Laetsch, T. W., Sorge, C., Sparks, R., Wan, S., Ceraulo, A., Kluczewska-Galka, A., Gámez-Cenzano, C., States, L. J., El Khouli, R., Aimone, P., Perraud, K., Kollar, G., Khanshan, F., Blumenstein, L., Brouri, F., & Giraudet, A. L. (2025). Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7). European Journal of Nuclear Medicine and Molecular Imaging, 52(13), 5211-5212. https://doi.org/10.1007/s00259-025-07344-6

Gaze, Mark N. ; Handkiewicz-Junak, Daria ; Hladun, Raquel et al. / Correction to : Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7). In: European Journal of Nuclear Medicine and Molecular Imaging. 2025 ; Vol. 52, No. 13. pp. 5211-5212.

@article{08b2e6b8184c42f3a3ad5d8b66dc0235,

title = "Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7)",

abstract = "The article Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study, written by Mark N. Gaze, Daria Handkiewicz-Junak, Raquel Hladun, Theodore W. Laetsch, Caryn Sorge, Richard Sparks, Simon Wan, Antony Ceraulo, Aneta Kluczewska-Galka, Cristina G{\'a}mez-Cenzano, Lisa J. States, Riham El Khouli, Paola Aimone, Kevin Perraud, Gabor Kollar, Fariba Khanshan, Lars Blumenstein, Fazia Brouri, and Anne-Laure Giraudet, was originally published under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.",

author = "Gaze, \{Mark N.\} and Daria Handkiewicz-Junak and Raquel Hladun and Laetsch, \{Theodore W.\} and Caryn Sorge and Richard Sparks and Simon Wan and Antony Ceraulo and Aneta Kluczewska-Galka and Cristina G{\'a}mez-Cenzano and States, \{Lisa J.\} and \{El Khouli\}, Riham and Paola Aimone and Kevin Perraud and Gabor Kollar and Fariba Khanshan and Lars Blumenstein and Fazia Brouri and Giraudet, \{Anne Laure\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = nov,

doi = "10.1007/s00259-025-07344-6",

language = "English",

volume = "52",

pages = "5211--5212",

number = "13",

}

Gaze, MN, Handkiewicz-Junak, D, Hladun, R, Laetsch, TW, Sorge, C, Sparks, R, Wan, S, Ceraulo, A, Kluczewska-Galka, A, Gámez-Cenzano, C, States, LJ, El Khouli, R, Aimone, P, Perraud, K, Kollar, G, Khanshan, F, Blumenstein, L, Brouri, F & Giraudet, AL 2025, 'Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7)', European Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 13, pp. 5211-5212. https://doi.org/10.1007/s00259-025-07344-6

Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7). / Gaze, Mark N.; Handkiewicz-Junak, Daria; Hladun, Raquel et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 52, No. 13, 11.2025, p. 5211-5212.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7)

AU - Gaze, Mark N.

AU - Handkiewicz-Junak, Daria

AU - Hladun, Raquel

AU - Laetsch, Theodore W.

AU - Sorge, Caryn

AU - Sparks, Richard

AU - Wan, Simon

AU - Ceraulo, Antony

AU - Kluczewska-Galka, Aneta

AU - Gámez-Cenzano, Cristina

AU - States, Lisa J.

AU - El Khouli, Riham

AU - Aimone, Paola

AU - Perraud, Kevin

AU - Kollar, Gabor

AU - Khanshan, Fariba

AU - Blumenstein, Lars

AU - Brouri, Fazia

AU - Giraudet, Anne Laure

PY - 2025/11

Y1 - 2025/11

N2 - The article Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study, written by Mark N. Gaze, Daria Handkiewicz-Junak, Raquel Hladun, Theodore W. Laetsch, Caryn Sorge, Richard Sparks, Simon Wan, Antony Ceraulo, Aneta Kluczewska-Galka, Cristina Gámez-Cenzano, Lisa J. States, Riham El Khouli, Paola Aimone, Kevin Perraud, Gabor Kollar, Fariba Khanshan, Lars Blumenstein, Fazia Brouri, and Anne-Laure Giraudet, was originally published under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.

AB - The article Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study, written by Mark N. Gaze, Daria Handkiewicz-Junak, Raquel Hladun, Theodore W. Laetsch, Caryn Sorge, Richard Sparks, Simon Wan, Antony Ceraulo, Aneta Kluczewska-Galka, Cristina Gámez-Cenzano, Lisa J. States, Riham El Khouli, Paola Aimone, Kevin Perraud, Gabor Kollar, Fariba Khanshan, Lars Blumenstein, Fazia Brouri, and Anne-Laure Giraudet, was originally published under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.

UR - https://www.scopus.com/pages/publications/105007105660

UR - https://www.scopus.com/pages/publications/105007105660#tab=citedBy

U2 - 10.1007/s00259-025-07344-6

DO - 10.1007/s00259-025-07344-6

M3 - Comment/debate

C2 - 40423778

AN - SCOPUS:105007105660

SN - 1619-7070

VL - 52

SP - 5211

EP - 5212

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 13

ER -

Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R et al. Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study (European Journal of Nuclear Medicine and Molecular Imaging, (2025), 52, 11, (4001-4015), 10.1007/s00259-025-07246-7). European Journal of Nuclear Medicine and Molecular Imaging. 2025 Nov;52(13):5211-5212. doi: 10.1007/s00259-025-07344-6